We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
PCSK9 单克隆抗体作用机制与临床研究进展.
- Authors
陈曦; 刘伯宁; 杨赟; 陈启; 王皓
- Abstract
Proprotein convertase subtilisin kexin type 9 (PCSK9) is a member of subtilisin-like proprotein convertase family. By interacting with low density lipoprotein receptor (LDLR) on the surface of hepatocyte, PCSK9 plays an important role in elevating the level of low density lipoprotein (LDL) and finally leading to hyperlipidemia. The PCSK9-inhibitor is now being an important and totally new therapeutic target to reduce the incidence of coronary heart disease through its function of lipid lowering. Especially, as the only theraputic antibody-drug with lipid-lowering function, the lipid depressing effect of monoclonal antibodies has crucial meaning for the therapy of familial transmissibility hyperlipidemia and the prevention of coronary heart disease. In this article, the mechanism of PCSK9, the research and development status, the safety and clinical efficacy of PCSK9 monoclonal antibodies will be briefly reviewed, with the purpose to provide important reference for research and development of monoclonal antibodies to PCSK9.
- Publication
Progress in Modern Biomedicine, 2016, Vol 16, Issue 6, p1156
- ISSN
1673-6273
- Publication type
Article
- DOI
10.13241/j.cnki.pmb.2016.06.045